Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham B15 2TT, UK.
Institute of Global Innovation, University of Birmingham, Birmingham B15 2TT, UK.
Psychol Med. 2023 Apr;53(5):2106-2115. doi: 10.1017/S003329172100386X. Epub 2021 Oct 1.
Cannabis use is a global public health issue associated with increased risks of developing mental health disorders, especially in young people. We aimed to investigate the relationships between cannabis exposure and risks of receiving mental illness diagnoses or treatment as outcomes.
A population based, retrospective, open cohort study using patients recorded in 'IQVIA medical research data', a UK primary care database. Read codes were used to confirm patients with recorded exposure to cannabis use who were matched up to two unexposed patients. We examined the risk of developing three categories of mental ill health: depression, anxiety or serious mental illness (SMI).
At study entry, the exposed cohort had an increased likelihood of having experienced mental ill health [odds ratio (OR) 4.13; 95% confidence interval (CI) 3.99-4.27] and mental ill health-related prescription (OR 2.95; 95% CI 2.86-3.05) compared to the unexposed group. During the study period we found that exposure to cannabis was associated with an increased risk of developing any mental disorder [adjusted hazard ratio (aHR) 2.73; 95% CI 2.59-2.88], also noted when examining by subtype of disorder: anxiety (aHR 2.46; 95% CI 2.29-2.64), depression (aHR 2.34; 95% CI 2.20-2.49) and SMI (aHR 6.41; 95% CI 5.42-7.57). These results remained robust in sensitivity analyses.
These findings point to the potential need for a public health approach to the management of people misusing cannabis. However, there is a gross under-recording of cannabis use in GP records, as seen by the prevalence of recorded cannabis exposure substantially lower than self-reported survey records.
大麻使用是一个全球性的公共卫生问题,与心理健康障碍风险增加有关,尤其是在年轻人中。我们旨在研究大麻暴露与精神疾病诊断或治疗的风险之间的关系。
这是一项基于人群的回顾性、开放性队列研究,使用的是英国初级保健数据库“IQVIA 医学研究数据”中的患者记录。阅读代码用于确认有记录的大麻使用暴露的患者,并与两名未暴露的患者相匹配。我们研究了三种心理健康障碍的发病风险:抑郁症、焦虑症或严重精神疾病(SMI)。
在研究开始时,暴露组出现心理健康问题(优势比 [OR] 4.13;95%置信区间 [CI] 3.99-4.27)和心理健康相关处方(OR 2.95;95% CI 2.86-3.05)的可能性更高。在研究期间,我们发现大麻暴露与任何精神障碍的发病风险增加相关(调整后的危险比 [aHR] 2.73;95% CI 2.59-2.88),当按疾病亚型检查时也注意到了这一点:焦虑症(aHR 2.46;95% CI 2.29-2.64)、抑郁症(aHR 2.34;95% CI 2.20-2.49)和 SMI(aHR 6.41;95% CI 5.42-7.57)。这些结果在敏感性分析中仍然稳健。
这些发现表明,需要采取公共卫生方法来管理滥用大麻的人。然而,在全科医生记录中对大麻使用的记录严重不足,这与记录的大麻暴露率明显低于自我报告的调查记录形成对比。